Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma.
Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Ahmad Halwani(University of Utah), Kim Linton(The Christie NHS Foundation Trust), Ian Chau(Royal Marsden NHS Foundation Trust), Hailing Lu(University of Washington), Alex F. Herrera(City of Hope), Roch Houot(Inserm), Frank J. Hsu(Sanofi (France)), Weiyun Z. Ai(City College of San Francisco), Javier Briones(Hospital de Sant Pau), Elizabeth H. Cull(Prisma Health), Iris Isufi(Yale University), Carlos Panizo, Jorge Chaves(Northwest Medical Specialties), Locke J. Bryan(Augusta University Health), Nancy L. Bartlett(Washington University in St. Louis), Béla Kis(Moffitt Cancer Center), Gottfried R. von Keudell(Memorial Sloan Kettering Cancer Center), Craig Okada(Oregon Health & Science University), Luis de la Cruz‐Merino
Cited by 2
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k